Navigation Links
Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
Date:3/16/2009

Cancer Targeted Therapeutic for Samtheo's Personalized Medicine Portfolio

NEW YORK, March 16 /PRNewswire/ -- Samtheo Biopharma LLC has entered into a license agreement, through its subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, gaining exclusive worldwide rights to a small molecule that selectively inhibits the activation of all three isoforms of Akt. Persistent activation of the Akt pathway has been found to play an important role in oncogenesis and chemo- and radiation-resistance and to be responsible for cancer cell proliferation, survival and invasiveness

Co-inventors are Jin Q. Cheng, M.D., Ph.D. and Said M. Sebti, Ph.D. from Moffitt. "This small molecule is a highly selective and potent inhibitor of Akt activation, leading to tumor growth arrest and induction of cancer cell death, and results in overcoming chemoresistance," said Dr. Cheng, Professor, Molecular Oncology Department at Moffitt. "Patients whose tumors contain persistently activated Akt are predicted to be more likely to respond to this inhibitor either as a single agent or in combination therapy," said Dr Sebti, Professor and Chair, Drug Discovery Department at Moffitt. "Akt is abnormally hyperactivated in many advanced malignancies and late stage tumors, such as breast, prostate, lung, pancreatic, liver, ovarian and colorectal cancers. Increased activation is also linked with drug and radiation resistance," said Dr. Cheng.

Through this license, Lyndor plans to develop and commercialize the new anti-cancer agent, which it refers to as LD-101, for refractory and resistant tumors as well as metastatic malignancies, addressing a huge unmet medical need. "Given time, most cancers will relapse, become resistant and, ultimately, refractory. In fact, most become metastatic before detection," said Susan Rosenbaum, Esq., Chairman and CEO of Samtheo. "Lyndor's agreement with Moffitt will enable Lyndor to develop this targeted therapeutic for personalized medicine in the treatment of patients with these difficult-to-treat diseases." Under the license agreement, Lyndor has agreed to pay Moffitt when various milestones are reached and provide Moffitt with running royalties on the sales of licensed products.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center (www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control.

About Lyndor

Lyndor is a privately-held subsidiary of Samtheo that acquired the exclusive, world-wide rights to its lead compound, LD-101, from Moffitt. Lyndor's interest in the treatment of cancer and development of LD-101 as an effective targeted therapeutic agent for personalized medicine is propelled by the desire to improve cancer treatment, offer patients greater life expectancy and provide a better quality of life.

About Samtheo

Samtheo is a privately-held company that invests in biotechnology companies focused on the delivery of personalized medicine through targeted therapeutics. Samtheo is in the business of acquisition, development and commercialization of innovative technology "with integrity", i.e., proprietary, novel intellectual property that will generate evidence-based, medically-effective and socially-assessable products. Samtheo's global mission is to improve health care and outcomes dramatically for patients with life-threatening diseases and unmet medical needs. Samtheo's press releases and other company information are available at www.samtheo.com.


'/>"/>
SOURCE Samtheo Biopharma LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 MarketNewsUpdates.com News Commentary  ... The ... are being pressured as of late due to the rise ... management has a dramatic impact on patient,s quality of life ... activities for identifying new forms of opioid formulations that prevent ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, ... their live events series, “Stem Cell Therapy: The Next Phase in the Evolution of ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... innovative Quantum peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered ... for high-pressure feed pumps in SU tangential flow filtration (TFF), virus filtration ...
(Date:3/22/2017)... BALTIMORE , March 22, 2017  Personal ... of its cancer testing contract with the U.S. ... earlier tumor profiling assay with the company,s new ... a comprehensive, clinically actionable pan-cancer profiling test that ... to assess potential patient response to checkpoint inhibitor ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):